A randomized clinical trial of exenatide on T2D

Jing Xu

Department of Endocrinology of Xinqiao Hospital, Army Medical University, Chongqing, P.R. China

ABSTRACT

Among the Chinese adults with diabetes, the proportion of overweight is 41.0%, the proportion of obesity is 24.3%, and the proportion of abdominal obesity is as high as 45.4% in 2008, which shows an increasing trend in recent years. Clinical studies have demonstrated that Asian people have higher levels of visceral fat than European and American populations. Obesity, especially abdominal obesity is closely associated with Diabetic Nephropathy (DN). Exenatide improves glycemic control and reduces body weight in patients with T2DM. In animal studies, exenatide can ameliorate albuminuria and improve kidney function. However, only a few studies evaluate the microalbuminuria in human. This study aims to investigate the effect of exenatide on urinary albumin, obese indices and glucose control in overweight/obese patients with type 2 diabetes.

ATTACHMENTS

Protocol.doc
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Protocol status: Working
We use this protocol and it's working.

Created: May 23, 2020

Last Modified: May 23, 2020

PROTOCOL integer ID:
37432

Keywords: Type 2 diabetes mellitus, Exenatide, Glycemic Control, urinary albumin